Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human papillomavirus type 45 (HPV45) is a high-risk, oncogenic virus strongly associated with the development of cervical cancer and other anogenital malignancies. The major capsid protein L1 of HPV45 self-assembles into icosahedral virus-like particles (VLPs) that present highly immunogenic, surface-exposed conformational epitopes. These conformational epitopes are the primary targets for neutralizing antibodies, which block viral attachment and entry into host cells. Prophylactic vaccines, such as the 9-valent HPV vaccine (Gardasil 9) and Walrinvax, utilize recombinant HPV45 L1 VLPs to stimulate the host immune system to produce type-specific neutralizing antibodies. Targeting these conformational epitopes provides robust protection against persistent HPV45 infection and its associated precancerous lesions and cancers. However, because these epitopes are highly conformation-dependent and type-specific, maintaining structural integrity during vaccine formulation and manufacturing is a critical therapeutic challenge.
Active immunization to induce neutralizing antibodies that block viral entry
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus type 45 major capsid protein L1 (HPV45 L1).